Beneficial read-through of a USH1C nonsense mutation by designed aminoglycoside NB30 in the retina

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 12, 2010, Pages 6671-6680

  Goldmann, Tobias ^a   Rebibo Sabbah, Annie ^b   Overlack, Nora ^a   Nudelman, Igor ^b   Belakhov, Valery ^b   Baasov, Timor ^b   Ben Yosef, Tamar ^b   Wolfrum, Uwe ^a   Nagel Wolfrum, Kerstin ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMINOGLYCOSIDE NB30; CELL PROTEIN; F ACTIN; GENTAMICIN; GLUTATHIONE TRANSFERASE; HARMONIN PROTEIN; PAROMOMYCIN; UNCLASSIFIED DRUG;

ACTIN FILAMENT; ARTICLE; BIOCOMPATIBILITY; CELL CULTURE; CONTROLLED STUDY; EXPLANT; GENE; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; NICK END LABELING; NONSENSE MUTATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; READ THROUGH NONSENSE MUTATION; RETINA EXPLANT; RNA TRANSLATION; USH1C GENE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AMINOGLYCOSIDES; ANIMALS; BLOTTING, WESTERN; CELL CULTURE TECHNIQUES; CODON, NONSENSE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPORATION; GENE EXPRESSION; GENTAMICINS; HEK293 CELLS; HUMANS; IN SITU NICK-END LABELING; MICE; MICE, INBRED C57BL; MICROSCOPY, FLUORESCENCE; PAROMOMYCIN; PROTEIN BIOSYNTHESIS; RETINA; TRANSFECTION;

EID: 79955450684     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-5741     Document Type: Article

References (54)

1. Davenport SLH, Omenn GS. The heterogeneity of Usher syndrome. Presented at: Vth International Conference on Birth Defects; August 1977; Montreal, Quebec, Canada.
2. Reiners J, Nagel-Wolfrum K, Jurgens K, Marker T, Wolfrum U. Molecular basis of human Usher syndrome: deciphering the meshes of the Usher protein network provides insights into the pathomechanisms of the Usher disease. Exp Eye Res. 2006;83:97-119.
3. Saihan Z, Webster AR, Luxon L, Bitner-Glindzicz M. Update on Usher syndrome. Curr Opin Neurol. 2009;22:19-27.
4. Damen GW, Beynon AJ, Krabbe PF, Mulder JJ, Mylanus EA. Cochlear implantation and quality of life in postlingually deaf adults: long-term follow-up. Otolaryngol Head Neck Surg. 2007;136:597-604.
5. Verpy E, Leibovici M, Zwaenepoel I, et al. A defect in harmonin, a PDZ domain-containing protein expressed in the inner ear sensory hair cells, underlies Usher syndrome type 1C. Nat Genet. 2000;26: 51-55.
6. Adato A, Michel V, Kikkawa Y, et al. Interactions in the network of Usher syndrome type 1 proteins. Hum Mol Genet. 2005;14:347-356.
7. Reiners J, Marker T, Jurgens K, Reidel B, Wolfrum U. Photoreceptor expression of the Usher syndrome type 1 protein protocadherin 15 (USH1F) and its interaction with the scaffold protein harmonin (USH1C). Mol Vis. 2005;11:347-355.
8. Reiners J, Van Wijk E, Marker T, et al. Scaffold protein harmonin (USH1C) provides molecular links between Usher syndrome type 1 and type 2. Hum Mol Genet. 2005;14:3933-3943.
9. Boëda B, El Amraoui A, Bahloul A, et al. Myosin VIIa, harmonin and cadherin 23, three Usher I gene products that cooperate to shape the sensory hair cell bundle. EMBO J. 2002;21:6689-6699.
10. Reiners J, Reidel B, El Amraoui A, et al. Differential distribution of harmonin isoforms and their possible role in Usher-1 protein complexes in mammalian photoreceptor cells. Invest Ophthalmol Vis Sci. 2003;44:5006-5015.
11. Ahmed ZM, Smith TN, Riazuddin S, et al. Nonsyndromic recessive deafness DFNB18 and Usher syndrome type IC are allelic mutations of USHIC. Hum Genet. 2002;110:527-531.
12. Ouyang XM, Xia XJ, Verpy E, et al. Mutations in the alternatively spliced exons of USH1C cause non-syndromic recessive deafness. Hum Genet. 2002;111:26-30.
13. Hainrichson M, Nudelman I, Baasov T. Designer aminoglycosides: the race to develop improved antibiotics and compounds for the treatment of human genetic diseases. Org Biomol Chem. 2008;6: 227-239.
14. Davis H, Deatherage BH, Ronsenblut B, Fernandez C, Kimura R, Smith CA. Modification of cochlear potentials produced by streptomycin poisoning and by extensive venous obstruction. Laryngoscope. 1958;68:596-627.
15. Sande MA, Mandell GL. Antimicrobial agents: the aminoglycosides. In: Gilman AG, Goodman LS, Rail TW, Murad F, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: Pergamon Press; 1990:1102.
16. Linde L, Kerem B. Introducing sense into nonsense in treatments of human genetic diseases. Trends Genet. 2008;24:552-563.
17. Bedwell DM, Kaenjak A, Benos DJ, et al. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med. 1997;3:1280-1284.
18. Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest. 1999;104:375-381.
19. Keeling KM, Brooks DA, Hopwood JJ, Li P, Thompson JN, Bedwell DM. Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. Hum Mol Genet. 2001;10:291-299.
20. Lai CH, Chun HH, Nahas SA, et al. Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. Proc Natl Acad Sci U S A. 2004;101:15676-5681.
21. Sangkuhl K, Schulz A, Rompler H, Yun J, Wess J, Schoneberg T. Aminoglycoside-mediated rescue of a disease-causing nonsense mutation in the V2 vasopressin receptor gene in vitro and in vivo. Hum Mol Genet. 2004;13:893-903.
22. Rebibo-Sabbah A, Nudelman I, Ahmed ZM, Baasov T, Ben-Yosef T. In vitro and ex vivo suppression by aminoglycosides of PCDH15 nonsense mutations underlying type 1 Usher syndrome. Hum Genet. 2007;122:373-381.
23. Politano L, Nigro G, Nigro V, et al. Gentamicin administration in Duchenne patients with premature stop codon: preliminary results. Acta Myol. 2003;22:15-21.
24. Wilschanski M, Yahav Y, Yaacov Y, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med. 2003;349:1433-1441.
25. Manuvakhova M, Keeling K, Bedwell DM. Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system. RNA. 2000;6:1044-1055.
26. Keeling KM, Bedwell DM. Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system. J Mol Med. 2002;80:367-376.
27. Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother. 1999;43:1003-1012.
28. Forge A, Schacht J. Aminoglycoside antibiotics. Audiol Neurootol. 2000;5:3-22.
29. Conway BP, Tabatabay CA, Campochiaro PA, D'Amico DJ, Hanninen LA, Kenyon KR. Gentamicin toxicity in the primate retina. Arch Ophthalmol. 1989;107:107-112.
30. Hancock HA, Guidry C, Read RW, Ready EL, Kraft TW. Acute aminoglycoside retinal toxicity in vivo and in vitro. Invest Ophthalmol Vis Sci. 2005;46:4804-4808.
31. Nudelman I, Rebibo-Sabbah A, Shallom-Shezifi D, et al. Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutations. Bioorg Med Chem Lett. 2006;16: 6310-6315.
32. Nudelman I, Rebibo-Sabbah A, Cherniavsky M, et al. Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations. J Med Chem. 2009;52:2836-2845.
33. Zwaenepoel I, Verpy E, Blanchard S, et al. Identification of three novel mutations in the USH1C gene and detection of thirty-one polymorphisms used for haplotype analysis. Hum Mutat. 2001;17: 34-41.
34. Gloeckner CJ, Boldt K, Schumacher A, Roepman R, Ueffing M. Anovel tandem affinity purification strategy for the efficient isolation and characterisation of native protein complexes. Proteomics. 2007;7:4228-4234.
35. Nagel-Wolfrum K, Buerger C, Wittig I, Butz K, Hoppe-Seyler F, Groner B. The interaction of specific peptide aptamers with the DNA binding domain and the dimerization domain of the transcriptionfactor Stat3 inhibits transactivation and induces apoptosis in tumor cells. Mol Cancer Res. 2004;2:170-182.
36. Maerker T, Van Wijk E, Overlack N, et al. A novel Usher protein network at the periciliary reloading point between molecular transport machineries in vertebrate photoreceptor cells. Hum Mol Genet. 2008;17:71-86.
37. Reidel B, Orisme W, Goldmann T, Smith WC, Wolfrum U. Photoreceptor vitality in organotypic cultures of mature vertebrate retinas validated by light-dependent molecular movements. Vision Res. 2006;46:4464-4471.
38. Overlack N, Maerker T, Latz M, Nagel-Wolfrum K, Wolfrum U. SANS (USH1G) expression in developing and mature mammalian retina. Vision Res. 2008;48:400-412.
39. Windoffer R, Kolsch A, Woll S, Leube RE. Focal adhesions are hotspots for keratin filament precursor formation. J Cell Biol. 2006;173:341-348.
40. Matsuda T, Cepko CL. Electroporation and RNA interference in the rodent retina in vivo and in vitro. Proc Natl Acad Sci U S A. 2004;101:16-22.
41. Bode C, Wolfrum U. Caspase-3 inhibitor reduces apoptotic photoreceptor cell death during inherited retinal degeneration in tubby mice. Mol Vis. 2003;9:144-150.
42. Reidel B, Goldmann T, Giessl A, Wolfrum U. The translocation of signaling molecules in dark adapting mammalian rod photoreceptor cells is dependent on the cytoskeleton. Cell Motil Cytoskeleton. 2008;65:785-800.
43. Orisme W, Li J, Goldmann T, Bolch S, Wolfrum U, Smith WC. Light-dependent translocation of arrestin in rod photoreceptors is signaled through a phospholipase C cascade and requires ATP. Cell Signal. 2010;22:447-456.
44. Lentz J, Pan F, Ng SS, Deininger P, Keats B. Ush1c216A knock-in mouse survives Katrina. Mutat Res. 2007;616:139-144.
45. Lentz JJ, Gordon WC, Farris HE, et al. Deafness and retinal degeneration in a novel USH1C knock-in mouse model. Dev Neurobiol. 2010;70:253-267.
46. Yang C, Feng J, Song W, et al. A mouse model for nonsense mutation bypass therapy shows a dramatic multiday response to geneticin. Proc Natl Acad Sci U S A. 2007;104:15394-15399.
47. Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet. 2008;372:719-727.
48. Maire I. Is genotype determination useful in predicting the clinical phenotype in lysosomal storage diseases? J Inherit Metab Dis. 2001;24(suppl 2):57-61.
49. Kellermayer R. Translational readthrough induction of pathogenic nonsense mutations. Eur J Med Genet. 2006;49:445-450.
50. Zingman LV, Park S, Olson TM, Alekseev AE, Terzic A. Aminoglycoside- induced translational read-through in disease: overcoming nonsense mutations by pharmacogenetic therapy. Clin Pharmacol Ther. 2007;81:99-103.
51. Guerin K, Gregory-Evans CY, Hodges MD, et al. Systemic aminoglycoside treatment in rodent models of retinitis pigmentosa. Exp Eye Res. 2008;87:197-207.
52. La Rocca PT, Baker F, Frantz JD, Szot RJ, Black HE, Schwartz E. Skin and mucous membrane ulceration in beagle dogs following oral dosing with an experimental aminoglycoside antibiotic. Fundam Appl Toxicol. 1985;5:986-990.
53. Chernikov VG, Terekhov SM, Krokhina TB, et al. Comparison of cytotoxicity of aminoglycoside antibiotics using a panel cellular biotest system. Bull Exp Biol Med. 2003;135:103-105.
54. Heier CR, DiDonato CJ. Translational readthrough by the aminoglycoside geneticin (G418) modulates SMN stability in vitro and improves motor function in SMA mice in vivo. Hum Mol Genet. 2009;18:1310-1322.